Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
60 NC counties and 1 VA county are under alert, including Wake, Cumberland, Durham, Johnston, and Orange counties.
Program
On WRAL at 6: Hundreds of millions of your tax dollars wasted. WRAL Investigates one of the most expensive city projects that went nowhere
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fsd Pharma Inc Cl B
(NQ:
HUGE
)
0.1494
-0.0006 (-0.40%)
Streaming Delayed Price
Updated: 2:39 PM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fsd Pharma Inc Cl B
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Launches New Program Targeting Unmet Medical Needs for Alcohol Misuse
February 14, 2023
Via
Investor Brand Network
FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse
February 14, 2023
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receipt of No Objection Letter from Health Canada Is Focus of Recent InvestmentPitch Media Video
February 09, 2023
Via
Investor Brand Network
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Health Canada Regulatory Approval to Move Forward with Phase 1 Trial
February 07, 2023
Via
Investor Brand Network
FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate
February 07, 2023
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Commences Recruitment in FSD201 Phase 2 Clinical Trial
January 30, 2023
Via
Investor Brand Network
Exposures
Product Safety
Recruiting Underway in FSD Pharma’s Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
January 30, 2023
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Spotlighted in InvestmentPitch Media Video Discussing Clinical Trial Application
January 19, 2023
Via
Investor Brand Network
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Submits Phase-1 Clinical Trial Application for Lucid-MS
January 17, 2023
Via
Investor Brand Network
FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation
January 17, 2023
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Authorized Share Repurchase Program
January 13, 2023
Via
Investor Brand Network
FSD Pharma Announces Share Repurchase Program
January 13, 2023
From
FSD Pharma Inc.
Via
Business Wire
6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements
January 10, 2023
Second week of 2023, and business is up and running. Let’s take a look at the announcements shared by some of the companies in the psychedelics space.
Via
Benzinga
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia
January 09, 2023
Via
Investor Brand Network
FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia
January 09, 2023
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Participate in Upcoming J.P. Morgan Healthcare Conference
January 06, 2023
Via
Investor Brand Network
FSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023
January 06, 2023
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Changes to the Board of Directors
November 30, 2022
Via
Investor Brand Network
FSD Pharma Announces Changes to the Board of Directors
November 28, 2022
From
FSD Pharma Inc.
Via
Business Wire
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Multimillion-Dollar Claim Has Been Dismissed
November 15, 2022
Via
Investor Brand Network
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Dismissal of Claim by Former CEO
November 10, 2022
Via
Investor Brand Network
FSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari
November 10, 2022
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
September 29, 2022
From
FSD Pharma Inc.
Via
Business Wire
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Participation at H.C. Wainwright 24th Annual Global Investment Conference
September 12, 2022
Via
Investor Brand Network
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Secures FDA and Health Canada Approval for Phase 2 Trial of FSD201
September 06, 2022
Via
Investor Brand Network
Exposures
Product Safety
FSD Pharma Participating in H.C. Wainwright 24th Annual Global Investment Conference, On-Demand Presentation Available
September 12, 2022
From
FSD Pharma Inc.
Via
Business Wire
FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome
September 06, 2022
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc.’s (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Lucid Psycheceuticals Files for Patent on Novel Formulations of Palmitoylethanolamide
July 13, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium
July 13, 2022
From
FSD Pharma Inc.
Via
Business Wire
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Report of Annual General Meeting of Shareholders
June 27, 2022
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.